PhaseBio Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on PhaseBio Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date PhaseBio Pharmaceuticals Inc Strategy Report
- Understand PhaseBio Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company's pipeline products comprise of PB2452, a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor; PB1046 is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) used for the treatment of pulmonary arterial hypertension. PhaseBio proprietary ELP Biopolymer technology platform extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism for periods of a week or longer from a single subcutaneous injection. The company develops drugs for the treatment of endocrine, metabolic and cardiovascular diseases. PhaseBio is headquartered in Malvern, Pennsylvania, the United States.
Headquarters
United States of America
Address
1 Great Valley Pkwy Ste 30, Malvern, Pennsylvania, 19355-1423
Website
phasebio.com
Telephone
1 610 9816500
No of Employees
60
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHASQ (OTC)
Revenue (2020)
$10.8M
3284.7%
(2020 vs 2019)
EPS
XYZ
Net Income (2020)
XYZ
-33%
(2020 vs 2019)
Net Profit Margin (2020)
XYZ
96.1%
(2020 vs 2019)
* As of and is in US$
PhaseBio Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| PB2452: |
| Ticagrelor Patients |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | PhaseBio Pharmaceuticals Inc | Applied Therapeutics Inc | Baudax Bio Inc | Karuna Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Malvern | New York | Malvern | Boston |
| State/Province | Pennsylvania | New York | Pennsylvania | Massachusetts |
| No. of Employees | 60 | 25 | 9 | 339 |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Clay Thorp | Chairman | Executive Board | 2014 | 53 |
| Jonathan P. Mow | Chief Executive Officer; Director | Executive Board | 2014 | 57 |
| John Sharp | Chief Financial Officer | Senior Management | 2016 | 57 |
| John Lee | Chief Medical Officer | Senior Management | 2016 | 54 |
| Lauren Richardson | Vice President - Regulatory and Quality | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer